Arachidonic acid facilitates experimental chronic osteomyelitis in rats.
Arachidonic acid was used as a facilitating agent in experimental rat Staphylococcus aureus osteomyelitis and compared with the more commonly used agent, sodium morrhuate. The injection of arachidonic acid or sodium morrhuate and S. aureus into rat tibiae caused increased quantitative bacterial bone counts, gross bone pathology, roentgenographic changes, and weight loss. The doses required to produce these changes appeared to be lower for arachidonic acid.
D000818:Animals; D016718:Arachidonic Acid; D001095:Arachidonic Acids / Q000633:toxicity*; D046508:Culture Techniques; D004195:Disease Models, Animal; D010019:Osteomyelitis / Q000000981:diagnostic imaging / Q000209:etiology* / Q000473:pathology; D011859:Radiography; D051381:Rats; D012976:Sodium Morrhuate / Q000633:toxicity; D013203:Staphylococcal Infections / Q000150:complications; D013211:Staphylococcus aureus / Q000472:pathogenicity
D001095:Arachidonic Acids; D016718:Arachidonic Acid; D012976:Sodium Morrhuate